Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy

A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer

(2014) Brendan Bender et al.   AAPS Journal

Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy

(2014) L. Nathan Tumey et al.   BIOCONJUGATE CHEMISTRY

Transglutaminase-Based Chemo-Enzymatic Conjugation Approach Yields Homogeneous Antibody–Drug Conjugates

(2014) Patrick Dennler et al.   BIOCONJUGATE CHEMISTRY

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma

(2014) Nizar M. Tannir et al.   INVESTIGATIONAL NEW DRUGS

Site-Specific Trastuzumab Maytansinoid Antibody–Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering

(2014) Thomas H. Pillow et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications

(2014) Andreas Maderna et al.   JOURNAL OF MEDICINAL CHEMISTRY

Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

(2014) Robert P Lyon et al.   NATURE BIOTECHNOLOGY

Mass Spectrometric Characterization of Transglutaminase Based Site-Specific Antibody–Drug Conjugates

(2013) Santiago E. Farias et al.   BIOCONJUGATE CHEMISTRY

Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates

(2013) Pavel Strop et al.   CHEMISTRY & BIOLOGY

Site-specific antibody drug conjugates for cancer therapy

(2013) Siler Panowski et al.   mAbs

Antibody-Drug Conjugates in Cancer Therapy

(2012) Eric L. Sievers et al.   Annual Review of Medicine

Drug-conjugated antibodies for the treatment of cancer

(2012) John M. Lambert   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

(2012) Sandhya Girish et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

(2012) Ben-Quan Shen et al.   NATURE BIOTECHNOLOGY

Site-Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase

(2010) Simone Jeger et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

(2010) J. R. Junutula et al.   CLINICAL CANCER RESEARCH

Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies

(2009) Laurent Ducry et al.   BIOCONJUGATE CHEMISTRY

Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates

(2008) Stephen C. Alley et al.   BIOCONJUGATE CHEMISTRY